Form 4: SOPHIA GENETICS SA: Insider Sells Shares for Tax Withholding

SOPHIA GENETICS SA reports that Chief Scientific Officer Zhenyu Xu sold shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

Summary

• Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS SA, sold a total of 4,736 ordinary shares on April 8th and 9th, 2026.
• These sales were conducted to satisfy tax withholding obligations arising from the vesting of restricted stock units on April 2nd and 3rd, 2026.
• The transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating they were not discretionary.
• The sales on April 8th involved 2,800 shares at a weighted average price of $4.839, resulting in 642,152 shares beneficially owned.
• The sales on April 9th involved 1,936 shares at a weighted average price of $4.7399, leaving 640,216 shares beneficially owned.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the insider sales are routine and executed under a pre-defined plan for tax purposes, rather than indicating a negative view of the company's prospects.

Positives

• The sales were executed under a Rule 10b5-1 trading plan, which is designed to provide an affirmative defense against allegations of insider trading.
• The transactions were for the purpose of covering tax withholding obligations, a common and expected event for executives upon vesting of equity awards.

Negatives

• An insider, the Chief Scientific Officer, has sold a portion of their holdings.
• The total number of shares sold is 4,736.

Risks

• While executed under a 10b5-1 plan, any significant insider selling can be perceived negatively by the market.
• The weighted average sale prices ($4.839 and $4.7399) may indicate a downward pressure on the stock price around the transaction dates.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports on past transactions.

Management Comments

• Sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider selling, even when conducted under a Rule 10b5-1 plan for tax purposes, is a common event for executives in the biotechnology and healthcare technology sectors, particularly following significant vesting events of equity compensation.

Stakeholder Impact

• Shareholders: May observe a slight increase in sell volume, but the nature of the transaction under a 10b5-1 plan mitigates concerns about negative insider sentiment.
• Employees: The transaction highlights the compensation structure for executives involving equity awards and associated tax implications.
• Management: Reinforces the use of established compliance procedures for equity transactions.

Next Steps

• The reporting person may continue to sell shares under the Rule 10b5-1 plan if further tax obligations arise or if the plan allows for additional sales.
• The company may receive written requests for detailed transaction information from the issuer, security holders, or the SEC staff.

Key Dates

Keywords

SOPHIA GENETICS SA, SOPH, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Tax Withholding, Restricted Stock Units, Beneficial Ownership, Zhenyu Xu